uracil and Local Neoplasm Recurrence
uracil has been researched along with Local Neoplasm Recurrence in 145 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Adjuvant therapy using a combination of oral protein-bound polysaccharide K and tegafur/uracil is highly effective in preventing the recurrence of colorectal cancer in Stage II or III patients, and increases overall survival in pathological TNM Stage III." | 9.10 | Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial. ( Ikeya, T; Kawashima, Y; Kawate, S; Kusaba, T; Morishita, Y; Nakajima, T; Nakamura, S; Ohwada, S; Roppongi, T; Takahashi, T; Yokomori, T, 2003) |
"A trial was designed to examine the combination of UFT and mitomycin (Mutamycin) plus tamoxifen (Nolvadex) as postoperative adjuvant therapy in the treatment of patients with stage II, estrogen receptor (ER)-positive primary breast cancer." | 9.09 | UFT and mitomycin plus tamoxifen for stage II, ER-positive breast cancer. Hokkaido ACETBC Study Group. ( Asaishi, K; Hata, Y; Hirata, K; Kubo, Y; Mito, M; Ogita, M; Tanabe, T; Uchino, J, 1999) |
"Low dose oral Folinic acid was used together with uracil with ftorafur (UFT) producing some response with low toxicity in advanced colorectal cancer." | 9.09 | Uracil with ftorafur and low dose oral folinic acid in advanced colorectal cancer. ( Arch-Yaemsuan, P; Boonnuch, W; Chakrapee-Sirisuk, S; Lert-Akayamanee, N; Lohsiriwat, D; Nimmanwudipong, T; Sinlarat, P; Srimuninnimit, V; Vathanophas, V, 2001) |
"Combination therapy consisting of cyclophosphamide (CPA), adriamycin (ADR), UFT and endocrine therapy of oophorectomy or tamoxifen (TAM) was given female patients with advanced or recurrent breast cancer." | 9.07 | [Efficacy of combination therapy consisting of cyclophosphamide, adriamycin, UFT and oophorectomy/tamoxifen for advanced or recurrent breast cancer]. ( Abe, R; Kiman, K; Kimijima, I; Nihei, M; Sakonji, M; Satomi, T; Suzuki, S; Tanaka, T, 1994) |
"Trifluridine/tipiracil (TFTD), with or without bevacizumab (Bev), and regorafenib are salvage chemotherapy options for metastatic colorectal cancer (mCRC)." | 8.12 | Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer. ( Boku, N; Hirano, H; Iwasa, S; Okita, N; Oshima, K; Shoji, H; Takashima, A, 2022) |
"This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age." | 7.91 | Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
"Elucidating the factors influencing severe neutropenia could aid in earlier management of neutropenia during oral trifluridine-tipiracil (TAS-102) chemotherapy in advanced and recurrent colorectal cancer (CRC)." | 7.88 | Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer. ( Ikeda, Y; Iwai, M; Kawachi, S; Kimura, M; Mitsuoka, M; Usami, E; Yasue, F; Yoshimura, T, 2018) |
"To establish the sufficient therapy for elderly colorectal cancer patients, we retrospectively compared postoperative Tegafur/Uracil (UFT; Taiho Pharmaceutical Co." | 7.75 | Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer. ( Takashima, S; Yoshitani, S, 2009) |
"We herein report the complete remission of multiple recurrent hepatocellular carcinomas (HCCs) by the oral administration of tegafur/uracil (UFT) alone." | 7.75 | Complete remission of multiple recurrent hepatocellular carcinomas by oral administration of enteric-coated tegafur/uracil in a patient with huge hepatocellular carcinoma extending to the inferior vena cava after hepatic resection: analysis of mRNA expres ( Asakawa, M; Fujii, H; Kono, H; Matsuda, M; Shiba, S, 2009) |
"We evaluated combination therapy for advanced and recurrent breast cancer with cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), UFT (uracil and tegafur), and tamoxifen (Nolvadex) (CAUT), designed as chemoendocrine therapy with a high antitumor effect and less severe adverse reactions." | 7.70 | Combination therapy for advanced breast cancer: cyclophosphamide, doxorubicin, UFT, and tamoxifen. ( Adachi, Y; Fukuda, M; Fukuma, E; Nakayama, Y; Nishikawa, T; Ogata, H; Ohta, T; Shimizu, K; Yamaguchi, S, 1999) |
"Since June 1984, 23 cases of progressive or recurrent breast cancers were treated with combination chemotherapy of VAM-UFT consisting of vincristine, adriamycin, mitomycin C and UFT." | 7.67 | [Vincristine, adriamycin, mitomycin-C and UFT (VAM-UFT) therapy in progressive or recurrent breast cancer]. ( Hozumi, T; Imamura, Y; Irie, K; Katou, J; Matsushita, K; Okutani, T; Oya, M; Yasutake, K; Yoshimura, Y, 1989) |
"The therapeutic efficacy of a regimen containing epirubicin (EPI) and vindesine (VDS) was evaluated in patients with breast cancer who were given a dose of 20 mg EPI and 3 mg VDS every 2 weeks." | 7.67 | [Combination chemotherapy using low-dose epirubicin and vindesine in patients with metastatic breast cancer]. ( Kawahara, T; Nakayama, H; Takatsuka, Y, 1988) |
"Recurrence of hepatocellular carcinoma (HCC) after surgery is frequent, and is an important factor adversely influencing the long-term survival of patients." | 6.82 | Administration of adjuvant oral tegafur/uracil chemotherapy post hepatocellular carcinoma resection: A randomized controlled trial. ( Ishizuka, M; Iso, Y; Kato, M; Kubota, K; Nemoto, T; Shimoda, M; Tago, K, 2016) |
"Frequent recurrence of hepatocellular carcinoma (HCC) after surgery remains a major clinical problem." | 6.72 | Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. ( Hasegawa, K; Ijichi, M; Imamura, H; Kokudo, N; Makuuchi, M; Matsuyama, Y; Sano, K; Sugawara, Y; Takayama, T, 2006) |
"Eniluracil, an effective inactivator of dihydropyrimidine dehydrogenase, allows for oral dosing of 5-fluorouracil (5-FU), which avoids the morbidity of continuous infusion 5-FU." | 6.71 | A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. ( Anscher, MS; Cohen, DP; Czito, BG; Ertel, PJ; Honeycutt, W; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Ludwig, KA; Mangum, SG; Mantyh, C; Morse, MA; Petros, WP; Seigler, HF; Spector, NL; Tyler, DS, 2004) |
"Trifluridine/Tipiracil is a relatively new drug used in refractory mCRC." | 5.91 | Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil. ( Bebyn, M; Koper, A; Koper, K; Śledzińska, P; Wileński, S, 2023) |
"We included stage II colorectal cancer patients who underwent curative surgery and were followed up for at least 5 years after surgery at the National Taiwan University Hospital between January 2008 and December 2012." | 5.62 | Metronomic chemotherapy with tegafur-uracil following radical resection in stage II colorectal cancer. ( Chen, TC; Jeng, YM; Liang, JT, 2021) |
"TAS-102 (trifluridine-tipiracil) has shown a significant overall survival benefit compared with placebo in patients with chemorefractory metastatic colorectal cancer." | 5.34 | TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. ( Krogh, M; Möller, S; Petersen, LN; Pfeiffer, P; Poulsen, LØ; Qvortrup, C; Thomsen, KG; Winther, SB; Yilmaz, M; Zitnjak, D, 2020) |
"Tissue samples from patients with pathologic ((p)) stage III colorectal cancer were tested for sensitivity to 5-fluorouracil (5-FU)." | 5.12 | An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer. ( Isogai, A; Kubota, S; Matsuoka, H; Nagaya, M; Tsukikawa, S; Watanabe, T, 2007) |
"Adjuvant therapy using a combination of oral protein-bound polysaccharide K and tegafur/uracil is highly effective in preventing the recurrence of colorectal cancer in Stage II or III patients, and increases overall survival in pathological TNM Stage III." | 5.10 | Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial. ( Ikeya, T; Kawashima, Y; Kawate, S; Kusaba, T; Morishita, Y; Nakajima, T; Nakamura, S; Ohwada, S; Roppongi, T; Takahashi, T; Yokomori, T, 2003) |
"Low dose oral Folinic acid was used together with uracil with ftorafur (UFT) producing some response with low toxicity in advanced colorectal cancer." | 5.09 | Uracil with ftorafur and low dose oral folinic acid in advanced colorectal cancer. ( Arch-Yaemsuan, P; Boonnuch, W; Chakrapee-Sirisuk, S; Lert-Akayamanee, N; Lohsiriwat, D; Nimmanwudipong, T; Sinlarat, P; Srimuninnimit, V; Vathanophas, V, 2001) |
"A trial was designed to examine the combination of UFT and mitomycin (Mutamycin) plus tamoxifen (Nolvadex) as postoperative adjuvant therapy in the treatment of patients with stage II, estrogen receptor (ER)-positive primary breast cancer." | 5.09 | UFT and mitomycin plus tamoxifen for stage II, ER-positive breast cancer. Hokkaido ACETBC Study Group. ( Asaishi, K; Hata, Y; Hirata, K; Kubo, Y; Mito, M; Ogita, M; Tanabe, T; Uchino, J, 1999) |
"Patients with advanced measurable colorectal cancer who had failed previous therapy with intravenous bolus 5-fluorouracil (5-FU) were eligible." | 5.09 | Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. ( Birkhofer, MJ; Ferreira, I; Meropol, NJ; Noel, D; Sonnichsen, DS, 1999) |
"Combination therapy consisting of cyclophosphamide (CPA), adriamycin (ADR), UFT and endocrine therapy of oophorectomy or tamoxifen (TAM) was given female patients with advanced or recurrent breast cancer." | 5.07 | [Efficacy of combination therapy consisting of cyclophosphamide, adriamycin, UFT and oophorectomy/tamoxifen for advanced or recurrent breast cancer]. ( Abe, R; Kiman, K; Kimijima, I; Nihei, M; Sakonji, M; Satomi, T; Suzuki, S; Tanaka, T, 1994) |
"We evaluated 63 patients with superficial bladder cancer (pTa, pTl) who were treated with instillation of bleomycin +/- bacillus Calmette-Guerin (BCG) and administration of uraciltfutraful (UFT) for prophylaxis of tumor recurrence after transurethral resection (TUR)." | 5.07 | [Prophylactic combination therapy after TUR of superficial bladder cancer]. ( Adachi, K; Ao, T; Endo, T; Kawakami, T; Koshiba, K; Mashimo, S; Uchida, T; Yokoyama, E, 1993) |
"To evaluate the effect of UFT, a mixture of ftorafur and uracil in a ratio of 1:4, in preventing postoperative recurrence of bladder cancer, we performed a randomized controlled study with a non-medication group as control." | 5.06 | [Prophylactic effect of UFT on the recurrence of bladder cancer]. ( Ejiri, S; Hisazumi, H; Kanda, S; Katsumi, T; Kitagawa, K; Mikawa, I; Miyagi, T; Naito, K; Nakamura, T; Saka, A, 1990) |
"Trifluridine/tipiracil (TFTD), with or without bevacizumab (Bev), and regorafenib are salvage chemotherapy options for metastatic colorectal cancer (mCRC)." | 4.12 | Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer. ( Boku, N; Hirano, H; Iwasa, S; Okita, N; Oshima, K; Shoji, H; Takashima, A, 2022) |
"For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival." | 4.12 | Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer. ( Ananda, S; Banks, S; Dunn, C; Gard, G; Gately, L; Gibbs, P; Jalali, A; Jennens, R; Khattak, A; Kosmider, S; Lee, B; Lee, M; Lim, L; Loft, M; McKendrick, J; Shapiro, JD; Tie, J; Wong, HL; Wong, R; Yeung, JM, 2022) |
"Trifluridine/tipiracil (TAS-102) is an important chemotherapeutic agent recommended by the Japanese guidelines as third- or fourth-line treatment for colorectal cancer." | 4.02 | [Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab]. ( Amagasa, H; Ami, K; Ando, M; Fukuda, A; Gan, S; Ganno, H; Iida, S; Imai, K; Kajiyama, D; Kawaguchi, M; Maeda, F; Motoyama, K; Okano, Y; Tokitou, F; Yamada, A, 2021) |
"This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age." | 3.91 | Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
"Elucidating the factors influencing severe neutropenia could aid in earlier management of neutropenia during oral trifluridine-tipiracil (TAS-102) chemotherapy in advanced and recurrent colorectal cancer (CRC)." | 3.88 | Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer. ( Ikeda, Y; Iwai, M; Kawachi, S; Kimura, M; Mitsuoka, M; Usami, E; Yasue, F; Yoshimura, T, 2018) |
"The effect of oral trifluridine-tipiracil (TAS-102)-induced neutropenia on survival of patients with advanced/recurrent colorectal cancer was investigated." | 3.85 | Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer ( Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2017) |
"To establish the sufficient therapy for elderly colorectal cancer patients, we retrospectively compared postoperative Tegafur/Uracil (UFT; Taiho Pharmaceutical Co." | 3.75 | Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer. ( Takashima, S; Yoshitani, S, 2009) |
"We herein report the complete remission of multiple recurrent hepatocellular carcinomas (HCCs) by the oral administration of tegafur/uracil (UFT) alone." | 3.75 | Complete remission of multiple recurrent hepatocellular carcinomas by oral administration of enteric-coated tegafur/uracil in a patient with huge hepatocellular carcinoma extending to the inferior vena cava after hepatic resection: analysis of mRNA expres ( Asakawa, M; Fujii, H; Kono, H; Matsuda, M; Shiba, S, 2009) |
"To evaluate ambulatory patient cancer chemotherapy, the clinical response, toxicities and survival time were analysed among 19 patients with non-curative or recurrent colorectal cancer who were treated by Uracil/Tegafur (UFT) plus oral Leucovorin (UZEL) for the past 2 years." | 3.73 | [Clinical study of ambulatory patient cancer chemotherapy for advanced colorectal cancer]. ( Fujiwara, H; Hamabe, Y; Ishida, T; Kaji, M; Mukai, H; Mukubou, H; Onishi, N; Sato, S; Toyokawa, A; Tsujimura, T; Tsukamoto, T; Wakahara, T; Wakita, K; Watanabe, A, 2005) |
"We evaluated combination therapy for advanced and recurrent breast cancer with cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), UFT (uracil and tegafur), and tamoxifen (Nolvadex) (CAUT), designed as chemoendocrine therapy with a high antitumor effect and less severe adverse reactions." | 3.70 | Combination therapy for advanced breast cancer: cyclophosphamide, doxorubicin, UFT, and tamoxifen. ( Adachi, Y; Fukuda, M; Fukuma, E; Nakayama, Y; Nishikawa, T; Ogata, H; Ohta, T; Shimizu, K; Yamaguchi, S, 1999) |
"Since June 1984, 23 cases of progressive or recurrent breast cancers were treated with combination chemotherapy of VAM-UFT consisting of vincristine, adriamycin, mitomycin C and UFT." | 3.67 | [Vincristine, adriamycin, mitomycin-C and UFT (VAM-UFT) therapy in progressive or recurrent breast cancer]. ( Hozumi, T; Imamura, Y; Irie, K; Katou, J; Matsushita, K; Okutani, T; Oya, M; Yasutake, K; Yoshimura, Y, 1989) |
"The therapeutic efficacy of a regimen containing epirubicin (EPI) and vindesine (VDS) was evaluated in patients with breast cancer who were given a dose of 20 mg EPI and 3 mg VDS every 2 weeks." | 3.67 | [Combination chemotherapy using low-dose epirubicin and vindesine in patients with metastatic breast cancer]. ( Kawahara, T; Nakayama, H; Takatsuka, Y, 1988) |
"Irinotecan was supplied at doses of 40, 50, 60, and 70 mg/m(2) by using a standard 3+3 design." | 2.82 | Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study. ( Chang, PM; Chen, SC; Yang, MH, 2016) |
"Patients aged 20-80 with stage II/III rectal cancer undergoing curative surgery without preoperative therapy were randomly assigned to receive UFT (500-600 mg/day on days 1-5, followed by 2 days rest) or S-1 (80-120 mg/day on days 1-28, followed by 14 days rest) for 1 year." | 2.82 | A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC). ( Baba, H; Emi, Y; Hamada, C; Ikejiri, K; Kakeji, Y; Kotake, M; Maeda, K; Maehara, Y; Matsuda, C; Matsuda, H; Munemoto, Y; Murata, A; Oki, E; Saji, S; Sasaki, K; Suenaga, T; Yoshida, K, 2016) |
"Recurrence of hepatocellular carcinoma (HCC) after surgery is frequent, and is an important factor adversely influencing the long-term survival of patients." | 2.82 | Administration of adjuvant oral tegafur/uracil chemotherapy post hepatocellular carcinoma resection: A randomized controlled trial. ( Ishizuka, M; Iso, Y; Kato, M; Kubota, K; Nemoto, T; Shimoda, M; Tago, K, 2016) |
"Etoposide 50 mg/m(2), UFT 250 mg/m(2) and leucovorin 90 mg (fixed dose) were dosed in 3 gifts approximately 8h apart for 14 days followed by 1 week rest every 3 weeks until progressive disease (PD)." | 2.74 | Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study. ( Aerts, JG; Gras, J; Hoogsteden, H; Pouw, E; Pronk, T; Salomé, J; Schmitz, PI; Surmont, V; Tan, KY; van Klaveren, RJ; Vernhout, R, 2009) |
"Twenty-two patients with metastatic colorectal cancer were enrolled in the phase I trial and 35 patients (including eight patients treated at level 4 during phase I) were evaluated in the phase II trial." | 2.73 | Phase I/II study of CPT-11 plus UFT in patients with advanced/recurrent colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Protocol 0102. ( Fukunaga, M; Furukawa, H; Gotoh, M; Ishida, H; Ishihara, R; Narahara, H; Okamura, S; Takiuchi, H; Tomita, N; Uedo, N, 2007) |
"Frequent recurrence of hepatocellular carcinoma (HCC) after surgery remains a major clinical problem." | 2.72 | Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. ( Hasegawa, K; Ijichi, M; Imamura, H; Kokudo, N; Makuuchi, M; Matsuyama, Y; Sano, K; Sugawara, Y; Takayama, T, 2006) |
") gemcitabine (GEM) at low dose plus oral chemotherapy with uracil-tegafur (UFT) and cyclophosphamide (CPA) in combination with radiotherapy (RT) against recurrent and advanced pancreatic cancers." | 2.71 | Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer. ( Endo, S; Hashimoto, K; Higami, T; Itakura, M; Koike, M; Maruyama, R; Nio, Y; Tsuji, M; Yamaguchi, K; Yano, S, 2005) |
" Administration of more than 2 courses was attempted for each patient, with the same dosage levels at all 3 scheduled steps." | 2.71 | [Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer]. ( Dono, K; Maruhashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takahashi, Y; Tujie, M; Umeshita, K, 2004) |
"Eniluracil, an effective inactivator of dihydropyrimidine dehydrogenase, allows for oral dosing of 5-fluorouracil (5-FU), which avoids the morbidity of continuous infusion 5-FU." | 2.71 | A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. ( Anscher, MS; Cohen, DP; Czito, BG; Ertel, PJ; Honeycutt, W; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Ludwig, KA; Mangum, SG; Mantyh, C; Morse, MA; Petros, WP; Seigler, HF; Spector, NL; Tyler, DS, 2004) |
" dosing without requiring any i." | 2.70 | Phase I study of oral uracil and Tegafur plus leucovorin and pelvic radiation in patients with recurrent rectal cancer. ( Dunst, J; Engenhart-Cabillic, R; Hess, CF; Hoffmann, W; Reese, T; Schiebe, ME; Schmidberger, H; Wenz, F, 2002) |
"5-Fluorouracil (5-FU) is an effective enhancer of radiation therapy (RT) in head and neck cancers." | 2.69 | Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. ( Brockstein, B; Dolan, ME; Haraf, DJ; Humerickhouse, RA; Kies, M; Ratain, MJ; Stenson, K; Sulzen, L; Vokes, EE, 1999) |
"For locally unresectable recurrent squamous cell carcinoma of the head and neck, we investigated two salvage chemotherapy regimens as second-line chemotherapy." | 2.69 | Prognosis after salvage chemotherapy for locally unresectable recurrent squamous cell carcinoma of the head and neck. ( Kawaida, M; Kitahara, S; Kohno, N; Ohmuma, T, 1999) |
"For 27 outpatients with advanced cancer of the digestive system including 15 cases of esophageal cancer, 4 cases of gastric cancer, 3 cases of colon cancer, 4 cases of pancreatic cancer and 1 case of gall bladder cancer, 4 to 6 week home adjuvant chemotherapy was performed." | 2.68 | [Combined chemotherapy with 5-FU and low dose CDDP for advanced or recurrent cancer of the digestive system and home anti-cancer chemotherapy]. ( Araki, H; Hiramatsu, Y; Kamiyama, Y; Kojima, Y; Nakagawa, A; Nakagawa, M; Ogura, T; Shirasaka, T, 1995) |
"According to the Japan Mammary Cancer Society's criteria of response, more than partial response was observed in 11 out of 32 cases (34." | 2.65 | [Clinical trial of UFT against disseminated breast cancer]. ( Harauchi, D; Itoh, S; Konishi, Y; Shinoto, M, 1984) |
"The preoperative diagnosis was giant hepatocellular carcinoma (HCC) of the right hepatic anterior region, and extended anterior segmentectomy of the liver was performed." | 2.42 | [Complete disappearance with oral UFT administration of recurrent hepatocellular carcinoma of the remnant liver and multiple lung metastasis after hepatic resection]. ( Hanazaki, K; Kawasaki, S; Kobayashi, A; Matsushita, A; Misawa, R; Miwa, S; Miyagawa, S; Nakagawa, K; Nakata, T; Noike, T; Nomura, K, 2003) |
"The common clinical presentations of head and neck cancer include early (stage I or II) disease, locally or regionally advanced (stage III or IV, M0) disease, and recurrent or metastatic disease (< 5% of patients)." | 2.40 | Oral 5-FU alternatives for the treatment of head and neck cancer. ( Brockstein, BE; Haraf, DJ; Humerickhouse, R; Vokes, EE, 1998) |
"Trifluridine/Tipiracil is a relatively new drug used in refractory mCRC." | 1.91 | Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil. ( Bebyn, M; Koper, A; Koper, K; Śledzińska, P; Wileński, S, 2023) |
"We included stage II colorectal cancer patients who underwent curative surgery and were followed up for at least 5 years after surgery at the National Taiwan University Hospital between January 2008 and December 2012." | 1.62 | Metronomic chemotherapy with tegafur-uracil following radical resection in stage II colorectal cancer. ( Chen, TC; Jeng, YM; Liang, JT, 2021) |
"A total of 118 rectal cancer patients receiving preoperative CRT were enrolled." | 1.51 | Identification of Predictors of Recurrence in Patients with Lower Rectal Cancer Undergoing Neoadjuvant Chemotherapy: A Direct Comparison of Short-Course and Long-Course Chemoradiotherapy. ( Araki, T; Fujikawa, H; Hiro, J; Ide, S; Kusunoki, M; Ohi, M; Okugawa, Y; Saigusa, S; Toiyama, Y; Yamamoto, A; Yasuda, H; Yoshiyama, S, 2019) |
" Details of serious adverse events (SAEs) were recorded." | 1.46 | Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. ( Albillos, A; Ampuero, J; Arenas, J; Bañares, R; Calleja, JL; Crespo, J; Diago, M; Fernandez, I; García-Eliz, M; García-Samaniego, J; Gea, F; Jorquera, F; Lens, S; Llaneras, J; Llerena, S; Mariño, Z; Morillas, RM; Muñoz, R; Navascues, CA; Pascasio, JM; Perelló, C; Rincón, D; Rodriguez, CF; Ruiz-Antorán, B; Sacristán, B; Serra, MA; Simon, MA; Torras, X; Turnes, J, 2017) |
"The tumor was diagnosed as breast carcinoma using a core needle biopsy." | 1.43 | [A Case of Primary Acinic Cell Carcinoma(ACC)of the Breast]. ( Iga, N; Ikeda, H; Ishizaki, M; Kawai, H; Nishi, H; Sugimoto, R; Waki, N; Yamashita, K; Yoshida, R, 2016) |
" Moreover, we recommend that, for patients with repeated treatment postponement due to neutropenia, the dosage should be fixed based on therapeutic efficacy and prognosis." | 1.43 | Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer. ( Asano, H; Go, M; Ito, D; Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2016) |
"Biliary papillomatosis is rare, and its pathogenic mechanisms are not yet clear." | 1.42 | Volume-reserving Surgery after Photodynamic Therapy for Biliary Papillomatosis: A Case Report. ( Cheong, CO; Kim, HK; Kim, KS; Lim, JH; Park, JS; Park, SW, 2015) |
"We recruited 93 rectal cancer patients who underwent neoadjuvant CRT and radical resection." | 1.40 | CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer. ( Hase, K; Hashiguchi, Y; Ishiguro, M; Kajiwara, Y; Kobayashi, H; Sekizawa, A; Shikina, A; Shinto, E; Ueno, H; Yamamoto, J, 2014) |
"We report a case of local recurrent colorectal cancer that has been treated successfully with low-dose oral chemotherapeutic agent." | 1.36 | [A case of local relapsed rectal cancer responding to low-dose S-1]. ( Fujita, S; Ikeda, N; Kanamura, T; Kojima, Y; Nakagawa, K; Ueno, M, 2010) |
"Sigmoidectomy was performed for sigmoid colon cancer in January 2002." | 1.36 | [A case of recurrent sigmoid colon cancer with adrenal and para-aortic lymph node metastasis successfully treated by operation and chemotherapy]. ( Doki, Y; Hirose, H; Ikeda, M; Kim, HM; Miyoshi, N; Mizushima, T; Mori, M; Okano, M; Sekimoto, M; Takemasa, I; Yamamoto, H; Yamashita, S, 2010) |
" The regimen of pre-op CCRT was a radiation dosage of 45 Gy in 20 fractions and oral tegafur-uracil (UFUR) and leucovorin." | 1.36 | The impact of preoperative chemoradiotherapy on advanced low rectal cancer. ( Chang, SC; Chen, WS; Jiang, JK; Kao, PS; Lee, RC; Liang, WY; Lin, JK; Lin, TC; Wang, HS; Wang, LW; Yang, SH, 2010) |
"These results suggest that the anticancer effect of S-1 can be predicted by performing UrBT 3 h after the initial oral S-1 administration." | 1.36 | Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1? ( Asai, S; Ishii, Y; Suzuki, S; Takahashi, Y; Takayama, T, 2010) |
"We report two cases of squamous cell carcinoma of upper urinary tract with hypercalcemia." | 1.35 | [Two cases of squamous cell carcinoma of upper urinary tract with hypercalcemia]. ( Kobayashi, Y; Matsuzaki, A; Terauchi, F; Washino, S, 2008) |
"For patients with T3N0M0 colon cancer without known risk factors, the necessity of chemotherapy has no definite consensus." | 1.35 | The necessity of chemotherapy in T3N0M0 colon cancer without risk factors. ( Cho, YB; Chun, HK; Kim, HC; Lee, WY; Yun, HR; Yun, SH, 2009) |
"Advanced ovarian cancer is a chemosensitive tumor and most patients initially respond to platinum-based combination chemotherapy with response rates of about 70%, including a high proportion of complete responses." | 1.35 | Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report. ( Aslan, Y; Buyukberber, S; Camci, C; Kalender, ME; Sevinc, A, 2009) |
"Primary liver cancer with lymph node metastasis was recognized as poor prognosis." | 1.35 | [A case report of combined hepatocellular-cholangiocarcinoma whose lymph node recurrence effectively treated with UFT]. ( Akagi, K; Dono, K; Fujita, J; Hata, T; Hayashi, S; Ikeda, K; Kagawa, Y; Kawanishi, K; Kitada, M; Munakata, K; Shimano, T; Shimizu, J; Takamoto, K; Watanabe, N; Yasumoto, T; Zenitani, M, 2009) |
"Advanced or recurrent pancreatic cancer can sometimes cause obstruction or stenosis of the portal vein (PV), resulting in various symptoms of portal hypertension (PH), such as ascites, pancytopenia, hemorrhagic tendencies and liver dysfunction." | 1.35 | Placement of an expandable metallic stent improves the efficacy of chemoradiotherapy for pancreatic cancer with malignant portal vein stenosis or obstruction. ( Endo, S; Hashimoto, K; Iguchi, C; Itakura, M; Koike, M; Nio, Y; Nishi, T; Omori, H; Sato, Y; Takamura, M; Takeda, H, 2009) |
"Thirty-three patients with rectal cancer underwent preoperative CRT." | 1.35 | Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. ( Ioue, Y; Kusunoki, M; Miki, C; Okugawa, Y; Saigusa, S; Tanaka, K; Toiyama, Y; Yokoe, T, 2009) |
" A dosage of 335 mg/m2/day of UFT was given perorally on daily schedule." | 1.34 | Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence. ( Akagi, Y; Fukushima, T; Ishibashi, N; Mori, S; Murakami, H; Ogata, Y; Shirouzu, K; Ushijima, M, 2007) |
"The data on 307 patients with colorectal cancer at stage II or III, who underwent potentially curative resection with lymphadenectomy, were reviewed." | 1.33 | The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. ( Ikeda, S; Ishibashi, N; Matono, K; Mizobe, T; Ogata, Y; Ogo, S; Ohkita, A; Ozasa, H; Sasatomi, T; Shirouzu, K, 2006) |
"The patient diagnosed as recurrent pancreatic cancer was treated with UFT combined gemcitabine (GEM) chemotherapy." | 1.33 | [A case of recurrent pancreatic cancer responding to TS-1 combined gemcitabine chemotherapy after UFT combined gemcitabine chemotherapy resulting progressive disease]. ( Kagaya, T; Kaneko, S; Kato, Y; Sunagozaka, H; Yamashita, T, 2006) |
"68 patients with clinical T3-4NxM0 rectal cancer were treated with surgery alone [Group II]." | 1.32 | Preoperative radio/chemo-radiotherapy in combination with intraoperative radiotherapy for T3-4Nx rectal cancer. ( Fukasawa, M; Ishikawa, K; Makuuchi, H; Murayama, C; Ohizumi, Y; Sadahiro, S; Saguchi, T; Suzuki, T; Yasuda, S, 2004) |
"The mean PyNPase activity of primary breast cancer, assayed by ELISA method, was 140." | 1.30 | [Prognostic effect of PyNPase (pyrimidine nucleoside phosphorylase) activity in breast cancer]. ( Baba, K; Fukuda, M; Higuchi, A; Masuyama, S; Matsuda, M; Matsumoto, H; Matsuoka, Y; Miyayama, H; Nagao, K; Nishimura, R; Uchino, S; Yamashita, H, 1998) |
"These two cases showed no recurrent liver cancers." | 1.28 | [Results of prophylactic intra-arterial infusion chemotherapy after hepatic resection in colorectal metastases]. ( Houjo, K; Kawano, N; Moriya, Y; Sugihara, K, 1990) |
"A Case of local recurrent breast cancer in a 45-year-old female with complete response to Combination of chemotherapy and topical administration of Adriamycin is reported." | 1.28 | [A case of local recurrent breast cancer with complete response to combination of systemic chemotherapy and topical use of adriamycin ointment]. ( Deguchi, S; Hokama, A; Kurihara, K; Muto, Y; Nomura, K; Toda, T, 1990) |
"This is a rare case of renal cell carcinoma with local recurrence and lung metastasis successfully treated with UFT." | 1.28 | [A case of renal cell carcinoma with lung metastasis and local recurrence effectively treated with nephrectomy and UFT]. ( Matsuda, M; Taguchi, H; Takaoka, K, 1992) |
"A case of local recurrence of rectal cancer was successfully treated by UFT combined with two-route CDDP chemotherapy under the AT-II induced hypertension." | 1.28 | [A case of local recurrence of rectal cancer successfully treated by UFT combined with two-route CDDP chemotherapy under the AT-II induced hypertension]. ( Ishizawa, T; Iwashige, H; Maenohara, S; Mure, H; Shimazu, H; Takao, S; Yamada, K, 1991) |
"He was diagnosed as having right renal cell carcinoma which had metastasized to the lung." | 1.28 | [A case of recurrence of a metastatic brain tumor which disappeared due to chemotherapy only]. ( Kayama, T; Ogawa, A; Sakurai, Y; Sato, K; Wada, T, 1990) |
"A 56-year-old woman with recurrent gastric cancer treated with PMU therapy, combined CDDP 75 mg/m2 i." | 1.27 | [PMU therapy of recurrent gastric cancer. A case report]. ( Matsuki, N; Miyata, R; Miyazaka, I; Noto, H; Ogino, S; Ohyama, S; Sakuma, H; Sawa, T; Yagi, M; Yonemura, Y, 1986) |
"In 8 cases of advanced and/or relapsed gastric cancer (7 cases advanced, 1 case relapsed), we undertook combination chemotherapy with systemic administration of cisplatin and celiac arterial infusion of carboquone intermittently under continuous administration of OK-432 i." | 1.27 | [Clinical study of combination chemotherapy using carboquone, cisplatin, UFT and OK-432 in 7 cases of advanced gastric cancers and a relapsed gastric cancer]. ( Horiuchi, M; Nakarai, I; Nasu, K; Shinoda, A, 1988) |
Research
Studies (145)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 11 (7.59) | 18.7374 |
1990's | 40 (27.59) | 18.2507 |
2000's | 48 (33.10) | 29.6817 |
2010's | 35 (24.14) | 24.3611 |
2020's | 11 (7.59) | 2.80 |
Authors
Authors | Studies |
---|---|
Jalali, A | 1 |
Gard, G | 1 |
Banks, S | 1 |
Dunn, C | 1 |
Wong, HL | 1 |
Wong, R | 1 |
Lee, M | 1 |
Gately, L | 1 |
Loft, M | 1 |
Shapiro, JD | 1 |
Kosmider, S | 1 |
Tie, J | 1 |
Ananda, S | 1 |
Yeung, JM | 1 |
Jennens, R | 1 |
Lee, B | 1 |
McKendrick, J | 1 |
Lim, L | 1 |
Khattak, A | 1 |
Gibbs, P | 1 |
Sadahiro, S | 3 |
Sakamoto, K | 2 |
Tsuchiya, T | 2 |
Takahashi, T | 4 |
Ohge, H | 2 |
Sato, T | 2 |
Kondo, K | 2 |
Ogata, Y | 4 |
Baba, H | 4 |
Itabashi, M | 2 |
Ikeda, M | 4 |
Hamada, M | 2 |
Maeda, K | 3 |
Masuko, H | 2 |
Takahashi, K | 5 |
Sakamoto, J | 1 |
Kusano, M | 1 |
Hyodo, I | 1 |
Taguri, M | 2 |
Morita, S | 2 |
Okamoto, K | 2 |
Kaku, R | 1 |
Oshio, Y | 1 |
Hanaoka, J | 1 |
Oshima, K | 1 |
Hirano, H | 1 |
Shoji, H | 1 |
Iwasa, S | 1 |
Okita, N | 1 |
Takashima, A | 1 |
Boku, N | 1 |
Miyashita, S | 1 |
Shimizu, T | 2 |
Ishizuka, M | 2 |
Niki, M | 1 |
Nishi, Y | 1 |
Shibuya, N | 1 |
Hachiya, H | 1 |
Matsumoto, T | 1 |
Sakuraoka, Y | 1 |
Shiraki, T | 1 |
Mori, S | 2 |
Iso, Y | 2 |
Irisawa, A | 1 |
Aoki, T | 2 |
Koper, A | 1 |
Wileński, S | 1 |
Śledzińska, P | 1 |
Bebyn, M | 1 |
Koper, K | 1 |
Liang, SK | 1 |
Wu, CW | 1 |
Chang, CI | 1 |
Keng, LT | 1 |
Lee, MR | 1 |
Wang, JY | 1 |
Ko, JC | 1 |
Liao, WY | 1 |
Chen, KY | 1 |
Ho, CC | 1 |
Shih, JY | 1 |
Yu, CJ | 1 |
Pfeiffer, P | 3 |
Yilmaz, M | 1 |
Möller, S | 1 |
Zitnjak, D | 1 |
Krogh, M | 1 |
Petersen, LN | 1 |
Poulsen, LØ | 1 |
Winther, SB | 1 |
Thomsen, KG | 1 |
Qvortrup, C | 1 |
Chen, TC | 1 |
Jeng, YM | 1 |
Liang, JT | 1 |
Hamada, S | 2 |
Komatsu, S | 1 |
Shibata, R | 1 |
Konishi, T | 1 |
Matsubara, D | 1 |
Soga, K | 1 |
Shimomura, K | 1 |
Ikeda, J | 1 |
Taniguchi, F | 1 |
Shioaki, Y | 1 |
Maeda, F | 1 |
Gan, S | 1 |
Yamada, A | 1 |
Kajiyama, D | 1 |
Tokitou, F | 1 |
Kawaguchi, M | 1 |
Amagasa, H | 1 |
Motoyama, K | 1 |
Ganno, H | 1 |
Imai, K | 1 |
Ami, K | 1 |
Iida, S | 1 |
Fukuda, A | 1 |
Ando, M | 1 |
Okano, Y | 1 |
Kimura, M | 4 |
Usami, E | 4 |
Iwai, M | 3 |
Teramachi, H | 3 |
Yoshimura, T | 4 |
Arnold, D | 1 |
Prager, GW | 1 |
Quintela, A | 1 |
Stein, A | 1 |
Moreno Vera, S | 1 |
Mounedji, N | 1 |
Taieb, J | 1 |
Yasue, F | 1 |
Kawachi, S | 1 |
Mitsuoka, M | 1 |
Ikeda, Y | 1 |
Matsuda, C | 3 |
Ishiguro, M | 3 |
Teramukai, S | 2 |
Kajiwara, Y | 2 |
Fujii, S | 2 |
Kinugasa, Y | 1 |
Nakamoto, Y | 2 |
Kotake, M | 3 |
Sakamoto, Y | 2 |
Kurachi, K | 2 |
Maeda, A | 1 |
Komori, K | 1 |
Tomita, N | 3 |
Shimada, Y | 1 |
Kotake, K | 1 |
Watanabe, M | 1 |
Mochizuki, H | 1 |
Nakagawa, Y | 1 |
Sugihara, K | 3 |
Yamamoto, A | 1 |
Toiyama, Y | 2 |
Okugawa, Y | 2 |
Saigusa, S | 2 |
Ide, S | 1 |
Fujikawa, H | 1 |
Hiro, J | 1 |
Yasuda, H | 1 |
Yoshiyama, S | 1 |
Ohi, M | 1 |
Araki, T | 1 |
Kusunoki, M | 2 |
Kashiwabara, K | 1 |
Semba, H | 1 |
Tsumura, S | 1 |
Hayashi, M | 1 |
Nakamura, K | 1 |
Terai, S | 1 |
Sakai, S | 1 |
Kinoshita, J | 2 |
Hayashi, H | 1 |
Oyama, K | 1 |
Miyashita, T | 1 |
Inokuchi, M | 1 |
Tajima, H | 1 |
Takamura, H | 1 |
Ninomiya, I | 1 |
Fushida, S | 1 |
Ohta, T | 2 |
Ueno, H | 2 |
Nakatani, E | 1 |
Ishikawa, T | 1 |
Uetake, H | 1 |
Egawa, T | 1 |
Yasumasa, K | 1 |
Murata, K | 1 |
Ikawa, O | 1 |
Shinji, S | 1 |
Murotani, K | 1 |
Matsui, S | 1 |
Preda, CM | 1 |
Baicus, C | 1 |
Sandra, I | 1 |
Oproiu, A | 1 |
Manuc, T | 1 |
Constantinescu, I | 1 |
Gavrila, D | 1 |
Diculescu, M | 1 |
Dumitru, R | 1 |
Vasilescu, C | 1 |
Tieranu, C | 1 |
Istratescu, D | 1 |
Voiosu, T | 1 |
Manuc, M | 1 |
Shinto, E | 1 |
Hase, K | 1 |
Hashiguchi, Y | 1 |
Sekizawa, A | 1 |
Shikina, A | 1 |
Kobayashi, H | 1 |
Yamamoto, J | 1 |
Draoui, N | 1 |
Schicke, O | 1 |
Seront, E | 1 |
Bouzin, C | 1 |
Sonveaux, P | 1 |
Riant, O | 1 |
Feron, O | 1 |
Maeda, T | 1 |
Hashimoto, K | 3 |
Ishida, T | 2 |
Yamashita, Y | 1 |
Saeki, H | 1 |
Kawanaka, H | 1 |
Uchiyama, H | 1 |
Ikeda, T | 2 |
Tsujitani, S | 1 |
Maehara, Y | 4 |
Twu, CW | 1 |
Wang, WY | 1 |
Chen, CC | 1 |
Liang, KL | 1 |
Jiang, RS | 1 |
Wu, CT | 1 |
Shih, YT | 1 |
Lin, PJ | 1 |
Liu, YC | 1 |
Lin, JC | 1 |
Tashiro, J | 1 |
Yamaguchi, S | 3 |
Ishii, T | 1 |
Suzuki, A | 1 |
Kondo, H | 1 |
Morita, Y | 1 |
Hara, K | 1 |
Koyama, I | 1 |
Hishida, T | 1 |
Tsuboi, M | 1 |
Shukuya, T | 1 |
Takamochi, K | 1 |
Sakurai, H | 1 |
Yoh, K | 1 |
Ohashi, Y | 1 |
Kunitoh, H | 1 |
Sasaki, K | 3 |
Nishimura, G | 1 |
Kodaira, S | 2 |
Kubota, K | 1 |
Nemoto, T | 1 |
Shimoda, M | 1 |
Kato, M | 1 |
Tago, K | 1 |
Cheong, CO | 1 |
Lim, JH | 1 |
Park, JS | 1 |
Park, SW | 1 |
Kim, HK | 1 |
Kim, KS | 1 |
Oki, E | 1 |
Murata, A | 1 |
Yoshida, K | 3 |
Ikejiri, K | 1 |
Munemoto, Y | 1 |
Suenaga, T | 1 |
Matsuda, H | 1 |
Emi, Y | 1 |
Kakeji, Y | 2 |
Hamada, C | 1 |
Saji, S | 1 |
Goldberg, R | 1 |
Chen, SC | 1 |
Chang, PM | 1 |
Yang, MH | 1 |
Go, M | 1 |
Ito, D | 1 |
Asano, H | 1 |
Kawai, H | 1 |
Sugimoto, R | 1 |
Iga, N | 1 |
Ikeda, H | 1 |
Yoshida, R | 1 |
Waki, N | 1 |
Ishizaki, M | 1 |
Nishi, H | 1 |
Yamashita, K | 1 |
Calleja, JL | 1 |
Crespo, J | 1 |
Rincón, D | 1 |
Ruiz-Antorán, B | 1 |
Fernandez, I | 1 |
Perelló, C | 1 |
Gea, F | 1 |
Lens, S | 1 |
García-Samaniego, J | 1 |
Sacristán, B | 1 |
García-Eliz, M | 1 |
Llerena, S | 1 |
Pascasio, JM | 1 |
Turnes, J | 1 |
Torras, X | 1 |
Morillas, RM | 1 |
Llaneras, J | 1 |
Serra, MA | 1 |
Diago, M | 1 |
Rodriguez, CF | 1 |
Ampuero, J | 1 |
Jorquera, F | 1 |
Simon, MA | 1 |
Arenas, J | 1 |
Navascues, CA | 1 |
Bañares, R | 1 |
Muñoz, R | 1 |
Albillos, A | 1 |
Mariño, Z | 1 |
Rivera, F | 1 |
Eugenia Vega-Villegas, M | 1 |
López, C | 1 |
Francisca López-Brea, M | 1 |
Rubio, A | 1 |
Del Valle, A | 1 |
García-Reija, F | 1 |
García-Montesinos, B | 1 |
Rodríguez-Iglesias, J | 1 |
Hinojo, C | 1 |
Márquez, R | 1 |
Angel Alonso-Bermejo, M | 1 |
Salcedo, M | 1 |
Blanco, Y | 1 |
Vega, N | 1 |
López-Tarruella, S | 1 |
Sanz-Ortiz, J | 1 |
Washino, S | 1 |
Terauchi, F | 1 |
Matsuzaki, A | 1 |
Kobayashi, Y | 1 |
Takagi, S | 1 |
Misawa, R | 2 |
Iinuma, N | 1 |
Uchikawa, Y | 1 |
Kameyama, H | 1 |
Takii, Y | 1 |
Nomura, T | 1 |
Nakagawa, S | 1 |
Yabusaki, H | 1 |
Tsuchiya, Y | 1 |
Nashimoto, A | 1 |
Tanaka, O | 1 |
Yoshitani, S | 1 |
Takashima, S | 1 |
Surmont, V | 1 |
Aerts, JG | 1 |
Pouw, E | 1 |
Tan, KY | 1 |
Vernhout, R | 1 |
Gras, J | 1 |
Salomé, J | 1 |
Pronk, T | 1 |
Schmitz, PI | 1 |
Hoogsteden, H | 1 |
van Klaveren, RJ | 1 |
Obuchi, T | 1 |
Sasaki, A | 1 |
Shimooki, O | 1 |
Minakawa, Y | 1 |
Abe, T | 1 |
Nitta, H | 1 |
Otsuka, K | 1 |
Koeda, K | 1 |
Ikeda, K | 2 |
Wakabayashi, G | 1 |
Huh, JW | 1 |
Kim, HR | 1 |
Matsuda, M | 3 |
Shiba, S | 1 |
Asakawa, M | 1 |
Kono, H | 1 |
Fujii, H | 1 |
Tanaka, K | 1 |
Yokoe, T | 1 |
Ioue, Y | 1 |
Miki, C | 1 |
Nio, Y | 3 |
Iguchi, C | 2 |
Itakura, M | 2 |
Nishi, T | 1 |
Takeda, H | 1 |
Takamura, M | 1 |
Omori, H | 1 |
Sato, Y | 3 |
Koike, M | 2 |
Endo, S | 2 |
Yun, HR | 1 |
Kim, HC | 1 |
Lee, WY | 1 |
Cho, YB | 1 |
Yun, SH | 1 |
Chun, HK | 1 |
Ishii, Y | 1 |
Suzuki, S | 2 |
Takahashi, Y | 2 |
Takayama, T | 2 |
Asai, S | 1 |
Hazra, A | 1 |
Selhub, J | 1 |
Chao, WH | 1 |
Ueland, PM | 1 |
Hunter, DJ | 1 |
Baron, JA | 1 |
Shimizu, J | 1 |
Hayashi, S | 1 |
Dono, K | 3 |
Yasumoto, T | 1 |
Zenitani, M | 1 |
Munakata, K | 1 |
Watanabe, N | 1 |
Takamoto, K | 1 |
Kagawa, Y | 2 |
Hata, T | 1 |
Kawanishi, K | 1 |
Fujita, J | 1 |
Akagi, K | 1 |
Kitada, M | 1 |
Shimano, T | 1 |
Kao, PS | 1 |
Chang, SC | 1 |
Wang, LW | 1 |
Lee, RC | 1 |
Liang, WY | 1 |
Lin, TC | 1 |
Chen, WS | 1 |
Jiang, JK | 1 |
Yang, SH | 1 |
Wang, HS | 1 |
Lin, JK | 1 |
Kim, HM | 2 |
Okano, M | 1 |
Miyoshi, N | 1 |
Hirose, H | 2 |
Yamashita, S | 2 |
Takemasa, I | 2 |
Mizushima, T | 3 |
Yamamoto, H | 3 |
Sekimoto, M | 2 |
Doki, Y | 2 |
Mori, M | 2 |
Nakagawa, K | 2 |
Ueno, M | 1 |
Kanamura, T | 1 |
Kojima, Y | 2 |
Fujita, S | 1 |
Ikeda, N | 1 |
Goto, H | 1 |
Ikenaga, M | 1 |
Yasui, M | 1 |
Miyazaki, M | 2 |
Mishima, H | 1 |
Tsujie, M | 2 |
Miyamoto, A | 3 |
Hirao, M | 1 |
Fujitani, K | 1 |
Nakamori, S | 3 |
Tsujinaka, T | 1 |
Katsuta, E | 1 |
Ohkubo, T | 1 |
Someno, Y | 1 |
Saguchi, M | 1 |
Aoyagi, H | 1 |
Takahata, T | 1 |
Hasegawa, K | 2 |
Kaneko, J | 1 |
Maejima, S | 1 |
Vestermark, LW | 1 |
Jensen, HA | 1 |
Matsushita, N | 1 |
Aruga, A | 1 |
Inoue, Y | 1 |
Kotera, Y | 1 |
Takeda, K | 1 |
Yamamoto, M | 1 |
Sugiyama, Y | 1 |
Kato, T | 2 |
Nakazato, H | 1 |
Ito, K | 1 |
Mizuno, I | 1 |
Kanemitsu, T | 1 |
Matsumoto, K | 1 |
Yamaguchi, A | 1 |
Nakai, K | 1 |
Inada, K | 1 |
Tatematsu, M | 1 |
Schiebe, ME | 1 |
Reese, T | 1 |
Wenz, F | 1 |
Schmidberger, H | 1 |
Engenhart-Cabillic, R | 1 |
Dunst, J | 1 |
Hess, CF | 1 |
Hoffmann, W | 2 |
Ishida, H | 2 |
Takeuchi, I | 1 |
Ohsawa, T | 1 |
Nakada, H | 1 |
Ishizuka, N | 1 |
Yokoyama, M | 2 |
Inokuma, S | 1 |
Suzuki, T | 2 |
Yamada, H | 1 |
Odaka, A | 1 |
Hoshino, T | 1 |
Murata, N | 1 |
Hashimoto, D | 1 |
Matsumoto, Y | 1 |
Miura, T | 1 |
Shimizu, C | 1 |
Watanabe, T | 2 |
Ohwada, S | 2 |
Kawate, S | 1 |
Ikeya, T | 1 |
Yokomori, T | 1 |
Kusaba, T | 1 |
Roppongi, T | 1 |
Nakamura, S | 1 |
Kawashima, Y | 2 |
Nakajima, T | 1 |
Morishita, Y | 1 |
Matsushita, A | 1 |
Hanazaki, K | 1 |
Noike, T | 1 |
Nakata, T | 1 |
Nomura, K | 2 |
Kobayashi, A | 1 |
Miwa, S | 1 |
Miyagawa, S | 1 |
Kawasaki, S | 1 |
Mori, T | 2 |
Yamaguchi, T | 1 |
Matsumoto, H | 2 |
Miyamoto, H | 1 |
Arai, K | 1 |
Iwasaki, Y | 1 |
Katayanagi, S | 1 |
Doi, T | 1 |
Ohtsu, A | 1 |
Nagasaki, E | 1 |
Furuta, N | 2 |
Shinozaki, E | 1 |
Tokutome, N | 1 |
Mishima, Y | 1 |
Chin, K | 1 |
Terui, Y | 1 |
Mizunuma, N | 1 |
Takahashi, S | 1 |
Itoh, Y | 1 |
Usui, N | 1 |
Hatake, K | 1 |
Kikkawa, N | 1 |
Iijima, S | 1 |
Handa, R | 1 |
Naoi, Y | 1 |
Oshima, S | 1 |
Kurokawa, E | 1 |
Tujie, M | 1 |
Maruhashi, S | 1 |
Nagano, H | 2 |
Umeshita, K | 2 |
Sakon, M | 2 |
Monden, M | 2 |
Czito, BG | 1 |
Hong, TJ | 1 |
Cohen, DP | 1 |
Tyler, DS | 1 |
Lee, CG | 1 |
Anscher, MS | 1 |
Ludwig, KA | 1 |
Seigler, HF | 1 |
Mantyh, C | 1 |
Morse, MA | 1 |
Lockhart, AC | 1 |
Petros, WP | 1 |
Honeycutt, W | 1 |
Spector, NL | 1 |
Ertel, PJ | 1 |
Mangum, SG | 1 |
Hurwitz, HI | 1 |
Watanabe, O | 1 |
Imamura, H | 2 |
Okabe, T | 1 |
Ogawa, K | 1 |
Haga, S | 1 |
Ishikawa, K | 2 |
Fukasawa, M | 1 |
Saguchi, T | 1 |
Yasuda, S | 1 |
Makuuchi, H | 1 |
Murayama, C | 1 |
Ohizumi, Y | 1 |
Altundag, O | 1 |
Altundag, K | 1 |
Gunduz, M | 1 |
Oya, R | 1 |
Ikemura, K | 1 |
Nakamura, M | 1 |
Kondo, M | 1 |
Yamamoto, T | 1 |
Ota, H | 1 |
Wada, H | 1 |
Damdinsuren, B | 1 |
Yang, Y | 1 |
Marubashi, S | 1 |
Yano, S | 2 |
Yamaguchi, K | 1 |
Tsuji, M | 1 |
Higami, T | 1 |
Maruyama, R | 1 |
Matono, K | 1 |
Sasatomi, T | 1 |
Ishibashi, N | 2 |
Ohkita, A | 1 |
Mizobe, T | 1 |
Ogo, S | 1 |
Ikeda, S | 1 |
Ozasa, H | 1 |
Shirouzu, K | 2 |
Kabashima, A | 1 |
Sakaguchi, Y | 1 |
Okita, K | 1 |
Yamamura, S | 1 |
Ojima, Y | 1 |
Nishizaki, T | 2 |
Tashiro, H | 1 |
Matsuzaka, T | 1 |
Toyokawa, A | 1 |
Tsujimura, T | 1 |
Hamabe, Y | 1 |
Sato, S | 1 |
Mukubou, H | 1 |
Wakahara, T | 1 |
Kaji, M | 1 |
Tsukamoto, T | 1 |
Wakita, K | 1 |
Onishi, N | 1 |
Watanabe, A | 1 |
Fujiwara, H | 1 |
Mukai, H | 1 |
Ito, T | 1 |
Mizuno, H | 1 |
Souma, Y | 1 |
Kainuma, S | 1 |
Yamanaka, H | 1 |
Ozawa, H | 1 |
Kanou, T | 1 |
Nakamori, Y | 1 |
Iwase, K | 1 |
Ogawa, T | 1 |
Makita, F | 1 |
Tanahashi, Y | 1 |
Ohya, T | 1 |
Tomizawa, N | 1 |
Satoh, Y | 1 |
Kobayashi, I | 1 |
Izumi, M | 1 |
Takeyoshi, I | 1 |
Hamada, K | 1 |
Minaguchi, S | 1 |
Togo, Y | 1 |
Toshihiko, T | 1 |
Koyama, T | 1 |
Kamio, M | 1 |
Sunagozaka, H | 1 |
Yamashita, T | 1 |
Kagaya, T | 1 |
Kato, Y | 1 |
Kaneko, S | 1 |
Inaba, Y | 1 |
Yamaura, H | 1 |
Shimamoto, H | 1 |
Nishiofuku, H | 1 |
Oyama, T | 1 |
Kanemitsu, Y | 1 |
Sawaki, A | 1 |
Arai, Y | 1 |
Muro, K | 1 |
Ijichi, M | 1 |
Matsuyama, Y | 1 |
Sano, K | 1 |
Sugawara, Y | 1 |
Kokudo, N | 1 |
Makuuchi, M | 1 |
Kawashima, M | 1 |
Hayashi, R | 1 |
Tahara, M | 1 |
Yamazaki, M | 1 |
Arahira, S | 1 |
Ogino, T | 1 |
Fukunaga, M | 1 |
Okamura, S | 1 |
Narahara, H | 1 |
Uedo, N | 1 |
Ishihara, R | 1 |
Furukawa, H | 1 |
Gotoh, M | 1 |
Takiuchi, H | 1 |
Isogai, A | 1 |
Nagaya, M | 1 |
Matsuoka, H | 1 |
Tsukikawa, S | 2 |
Kubota, S | 1 |
Akagi, Y | 1 |
Ushijima, M | 1 |
Murakami, H | 1 |
Fukushima, T | 1 |
Camci, C | 1 |
Sevinc, A | 1 |
Aslan, Y | 1 |
Kalender, ME | 1 |
Buyukberber, S | 1 |
Akiyama, J | 1 |
Sagara, Y | 1 |
Takeda, Y | 1 |
Itoh, S | 1 |
Konishi, Y | 1 |
Harauchi, D | 1 |
Shinoto, M | 1 |
Kunitomo, K | 1 |
Kuwashima, T | 1 |
Korematsu, H | 1 |
Tamura, T | 1 |
Yoshikawa, H | 1 |
Toyosaki, M | 1 |
Komi, N | 1 |
Ao, T | 1 |
Uchida, T | 1 |
Yokoyama, E | 1 |
Kawakami, T | 1 |
Adachi, K | 1 |
Mashimo, S | 1 |
Endo, T | 1 |
Koshiba, K | 1 |
Takenaka, K | 1 |
Korenaga, D | 1 |
Hiroshige, K | 1 |
Sugimachi, K | 3 |
Takano, S | 1 |
Moriguchi, M | 1 |
Seki, N | 2 |
Higaki, T | 1 |
Watanabe, Y | 1 |
Ito, Y | 1 |
Oishi, H | 1 |
Nakata, Y | 1 |
Kono, S | 1 |
Kiman, K | 1 |
Satomi, T | 1 |
Sakonji, M | 1 |
Nihei, M | 1 |
Tanaka, T | 1 |
Kimijima, I | 1 |
Abe, R | 1 |
Okuyama, T | 1 |
Furusawa, M | 1 |
Yamada, Y | 1 |
Washida, H | 1 |
Tozawa, K | 1 |
Honma, H | 1 |
Kang, K | 1 |
Kubota, Y | 1 |
Hosaka, M | 1 |
Fukushima, S | 1 |
Kondo, I | 2 |
Ogura, T | 1 |
Hiramatsu, Y | 1 |
Araki, H | 1 |
Nakagawa, A | 1 |
Nakagawa, M | 1 |
Kamiyama, Y | 1 |
Shirasaka, T | 1 |
Asano, M | 1 |
Yasuno, M | 1 |
Naito, S | 1 |
Kumazawa, J | 1 |
Omoto, T | 1 |
Iguchi, A | 1 |
Sagiyama, K | 1 |
Osada, Y | 1 |
Hiratsuka, Y | 1 |
Ogawa, M | 1 |
Kakegawa, T | 1 |
Tomita, M | 1 |
Nishimura, R | 1 |
Nagao, K | 1 |
Miyayama, H | 1 |
Baba, K | 1 |
Matsuoka, Y | 3 |
Yamashita, H | 1 |
Fukuda, M | 3 |
Higuchi, A | 1 |
Masuyama, S | 1 |
Uchino, S | 1 |
Nishino, H | 1 |
Tanaka, H | 1 |
Kanazawa, T | 1 |
Miyata, M | 1 |
Kitamura, K | 1 |
Vokes, EE | 2 |
Brockstein, BE | 1 |
Humerickhouse, R | 1 |
Haraf, DJ | 2 |
Meropol, NJ | 1 |
Sonnichsen, DS | 1 |
Birkhofer, MJ | 1 |
Ferreira, I | 1 |
Noel, D | 1 |
Humerickhouse, RA | 1 |
Dolan, ME | 1 |
Brockstein, B | 1 |
Stenson, K | 1 |
Kies, M | 1 |
Sulzen, L | 1 |
Ratain, MJ | 1 |
González Barón, M | 1 |
Nakayama, Y | 1 |
Ogata, H | 1 |
Shimizu, K | 1 |
Nishikawa, T | 1 |
Adachi, Y | 1 |
Fukuma, E | 1 |
Hata, Y | 1 |
Uchino, J | 1 |
Asaishi, K | 1 |
Kubo, Y | 1 |
Mito, M | 1 |
Tanabe, T | 1 |
Ogita, M | 1 |
Hirata, K | 1 |
Schiebe, M | 1 |
Dethling, J | 1 |
Martin, C | 1 |
Watanabe, H | 2 |
Ohishi, T | 1 |
Abe, M | 1 |
Sumi, S | 1 |
Tamura, K | 1 |
Kohno, N | 1 |
Kitahara, S | 1 |
Kawaida, M | 1 |
Ohmuma, T | 1 |
Kusama, M | 1 |
Kaise, H | 1 |
Nakayama, S | 1 |
Oota, D | 1 |
Shimizu, H | 1 |
Koyanagi, Y | 1 |
Knowling, M | 1 |
Browman, G | 1 |
Siu, L | 1 |
Khoo, K | 1 |
Cooke, A | 1 |
Tannock, I | 1 |
Klaassen, D | 1 |
Cripps, C | 1 |
Goss, G | 1 |
Matthews, S | 1 |
Clarke, R | 1 |
Seymour, L | 1 |
Chakrapee-Sirisuk, S | 1 |
Sinlarat, P | 1 |
Lohsiriwat, D | 1 |
Lert-Akayamanee, N | 1 |
Nimmanwudipong, T | 1 |
Srimuninnimit, V | 1 |
Vathanophas, V | 1 |
Arch-Yaemsuan, P | 1 |
Boonnuch, W | 1 |
Yoshida, O | 1 |
Kakehi, Y | 1 |
Nishio, Y | 1 |
Tomoyoshi, T | 1 |
Konami, T | 1 |
Usui, T | 1 |
Igawa, M | 1 |
Takenaka, I | 1 |
Fujita, K | 1 |
Masuda, F | 2 |
Nakada, J | 1 |
Hirao, Y | 1 |
Okajima, E | 1 |
Ozono, S | 1 |
Samma, S | 1 |
Hiramatsu, T | 1 |
Babaya, K | 1 |
Watanabe, S | 1 |
Maruyama, Y | 1 |
Okuda, T | 1 |
Onda, M | 1 |
Tokunaga, A | 1 |
Teramoto, T | 1 |
Fujita, I | 1 |
Mizutani, T | 1 |
Kiyama, T | 1 |
Nishi, K | 1 |
Okazaki, S | 1 |
Kyono, S | 1 |
Moreira, LF | 1 |
Iwagaki, H | 1 |
Hizuta, A | 1 |
Sakagami, K | 1 |
Mimura, H | 1 |
Orita, K | 1 |
Taguchi, H | 1 |
Takaoka, K | 1 |
Mori, Y | 1 |
Torii, S | 1 |
Kobari, T | 1 |
Hosobe, T | 1 |
Namatame, K | 1 |
Sasaki, E | 1 |
Koh, Y | 1 |
Shimada, K | 1 |
Nakamura, T | 2 |
Hirose, T | 1 |
Ookubo, M | 1 |
Nakayoshi, A | 1 |
Iwashige, H | 1 |
Yamada, K | 1 |
Mure, H | 1 |
Maenohara, S | 1 |
Takao, S | 1 |
Ishizawa, T | 1 |
Shimazu, H | 1 |
Sato, K | 1 |
Kayama, T | 1 |
Sakurai, Y | 1 |
Ogawa, A | 1 |
Wada, T | 1 |
Sekiguchi, I | 1 |
Suzuki, M | 1 |
Aida, I | 1 |
Tamada, T | 1 |
Nishida, M | 1 |
Naito, K | 1 |
Hisazumi, H | 1 |
Saka, A | 1 |
Kanda, S | 1 |
Mikawa, I | 1 |
Ejiri, S | 1 |
Miyagi, T | 1 |
Katsumi, T | 1 |
Kitagawa, K | 1 |
Fujita, Y | 1 |
Ota, J | 1 |
Fujita, M | 1 |
Sugimoto, T | 1 |
Taguchi, T | 1 |
Kawano, N | 1 |
Moriya, Y | 1 |
Houjo, K | 1 |
Komoriyama, H | 1 |
Imaki, S | 1 |
Morikubo, M | 1 |
Asakura, T | 1 |
Okamura, R | 1 |
Kanasugi, K | 1 |
Oda, H | 1 |
Nabeshima, S | 1 |
Oda, T | 1 |
Nishio, S | 1 |
Iwata, H | 1 |
Takeuchi, M | 1 |
Matsumoto, A | 1 |
Terado, T | 1 |
Deguchi, S | 1 |
Kurihara, K | 1 |
Hokama, A | 1 |
Muto, Y | 1 |
Toda, T | 1 |
Tsuji, H | 2 |
Tsujii, H | 2 |
Kamada, T | 2 |
Takamura, A | 2 |
Shirato, H | 1 |
Irie, G | 2 |
Aoki, Y | 1 |
Tabuse, Y | 1 |
Tanimura, H | 1 |
Katsumi, M | 1 |
Asae, M | 1 |
Ichimiya, G | 1 |
Imai, T | 1 |
Ooshima, K | 1 |
Kakihara, M | 1 |
Kashitani, M | 1 |
Usubuchi, H | 1 |
Yasutake, K | 1 |
Imamura, Y | 1 |
Yoshimura, Y | 1 |
Oya, M | 1 |
Matsushita, K | 1 |
Hozumi, T | 1 |
Katou, J | 1 |
Okutani, T | 1 |
Irie, K | 1 |
Takatsuka, Y | 1 |
Nakayama, H | 1 |
Kawahara, T | 1 |
Ohyama, S | 1 |
Yonemura, Y | 1 |
Matsuki, N | 1 |
Miyata, R | 1 |
Noto, H | 1 |
Sakuma, H | 1 |
Yagi, M | 1 |
Sawa, T | 1 |
Ogino, S | 1 |
Miyazaka, I | 1 |
Nasu, K | 1 |
Nakarai, I | 1 |
Horiuchi, M | 1 |
Shinoda, A | 1 |
Mardakhiashvili, ShI | 1 |
Clinical Trials (9)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized, Controlled Phase II Clinical Trial of Fruquintinib Combined With Raltitrexed Versus Fruquintinib Monotherapy in Patients With Advanced Colorectal Cancer Who Had Failed Second-line or Above Standard Chemotherapy[NCT04582981] | Phase 2 | 136 participants (Anticipated) | Interventional | 2020-09-28 | Recruiting | ||
Randomized Phase III Trial of Adjuvant Chemotherapy With UFT vs. Observation in Curatively Resected Stage II Colon Cancer[NCT00392899] | Phase 3 | 2,025 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
1922GCCC: PHASE 2 STUDY OF PEMBROLIZUMAB AND BAVITUXIMAB FOR PROGRESSIVE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK[NCT04150900] | Phase 2 | 7 participants (Actual) | Interventional | 2020-01-13 | Active, not recruiting | ||
Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3, Multicentre, Randomised Controlled Trial (CAN)[NCT02958111] | Phase 3 | 406 participants (Actual) | Interventional | 2017-01-31 | Active, not recruiting | ||
Randomized, Placebo-controlled, Double-blind Phase II Clinical Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Immunotherapy Combined With Concurrent Chemoradiotherapy for High-risk Nasopharyngeal Carcinoma[NCT03925090] | Phase 2 | 150 participants (Anticipated) | Interventional | 2019-12-08 | Active, not recruiting | ||
Phase Ⅲ Trial of Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy (GP Versus PF) in Patients With N2-3 Nasopharyngeal Carcinoma[NCT03321539] | Phase 3 | 216 participants (Anticipated) | Interventional | 2017-10-30 | Active, not recruiting | ||
A Phase Ib/II Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).[NCT05927857] | Phase 1/Phase 2 | 45 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | ||
Aspirin/Folate Prevention of Large Bowel Polyps[NCT00272324] | Phase 2/Phase 3 | 1,121 participants | Interventional | 1992-02-29 | Completed | ||
A Randomized Controlled Phase III Adjuvant Trial of High-Dose Bolus IL-2 in Patients With High-Risk Renal Cell Carcinoma[NCT00003126] | Phase 3 | 69 participants (Actual) | Interventional | 1997-06-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Reviews
7 reviews available for uracil and Local Neoplasm Recurrence
Article | Year |
---|---|
Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.
Topics: Colorectal Neoplasms; Disease Progression; Drug Combinations; Drugs, Investigational; Humans; Neopla | 2018 |
[Recent advance in adjuvant therapy for breast cancer].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2002 |
[Complete disappearance with oral UFT administration of recurrent hepatocellular carcinoma of the remnant liver and multiple lung metastasis after hepatic resection].
Topics: Administration, Oral; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2003 |
[Effect of systemic chemotherapy by 5-FU with low dose CDDP (in the hospital) and UFT with low dose CDDP (in outpatient clinic) in unresectable recurrent colorectal cancer].
Topics: Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Ne | 2003 |
[Present status of chemotherapy for colorectal cancer in countries outside of Japan].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2003 |
Oral 5-FU alternatives for the treatment of head and neck cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1998 |
[Oral fluoropyrimidines in oncology].
Topics: Administration, Oral; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplas | 1998 |
Trials
49 trials available for uracil and Local Neoplasm Recurrence
Article | Year |
---|---|
Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2022 |
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combin | 2020 |
A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2018 |
Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial.
Topics: Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Epithelial-Mesenchymal Trans | 2019 |
Treatment Rationale and Study Design for Clinical Trial on the Efficacy of UFT/LV for Stage II Colorectal Cancer With Risk Factors for Recurrence (JFMC46-1201).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Humans | 2015 |
Administration of adjuvant oral tegafur/uracil chemotherapy post hepatocellular carcinoma resection: A randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemot | 2016 |
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2016 |
Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; | 2016 |
Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study.
Topics: Administration, Oral; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2009 |
High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Feas | 2012 |
Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Colorectal Neoplasms; | 2013 |
Retrospective study on thymidylate synthase as a predictor of outcome and sensitivity to adjuvant chemotherapy in patients with curatively resected colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorecta | 2002 |
Phase I study of oral uracil and Tegafur plus leucovorin and pelvic radiation in patients with recurrent rectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therap | 2002 |
[Hepatic recurrence after prophylactic hepatic arterial infusion of 5-fluorouracil for Dukes' C colorectal cancer--correlation with the expression of dihydropyrimidine dehydrogenase in the primary tumor].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; C | 2003 |
[Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; D | 2004 |
A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2004 |
[Clinical usefulness of UFT and cyclophosphamide as salvage chemotherapy for patients with metastatic breast cancer].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therap | 2005 |
High-dose radiotherapy and concurrent UFT plus l-leucovorin in locally advanced rectal cancer: a phase I trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD11b Antigen; CD57 Antigens; CD8 Antig | 2006 |
Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy | 2006 |
Phase I/II study of CPT-11 plus UFT in patients with advanced/recurrent colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Protocol 0102.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; An | 2007 |
An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Combined Modalit | 2007 |
[Clinical trial of UFT against disseminated breast cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 1984 |
[Prophylactic combination therapy after TUR of superficial bladder cancer].
Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic C | 1993 |
[The significance of portal infusion chemotherapy for prevention of recurrence in residual liver after hepatectomy for metastases from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; He | 1994 |
[Efficacy of combination therapy consisting of cyclophosphamide, adriamycin, UFT and oophorectomy/tamoxifen for advanced or recurrent breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1994 |
Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modali | 1994 |
Prophylactic oral UFT therapy for superficial bladder cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 1993 |
[Combined chemotherapy with 5-FU and low dose CDDP for advanced or recurrent cancer of the digestive system and home anti-cancer chemotherapy].
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 1995 |
[Low-dose cisplatin added to continuous infusion of 5-fluorouracil or oral administration of UFT for inoperable advanced or recurrent colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Coloni | 1997 |
Postoperative UFT adjuvant and the risk factors for recurrence in renal cell carcinoma: a long-term follow-up study. Kyushu University Urological Oncology Group.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Combinations; F | 1997 |
Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Diseas | 1997 |
Postoperative adjuvant chemotherapy with mitomycin C and UFT for rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinatio | 1997 |
Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bi | 1999 |
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combin | 1999 |
UFT and mitomycin plus tamoxifen for stage II, ER-positive breast cancer. Hokkaido ACETBC Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Di | 1999 |
UFT plus calcium folinate plus radiotherapy for recurrent rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Humans; Leucovorin; Neoplasm Recu | 1999 |
Prognosis after salvage chemotherapy for locally unresectable recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1999 |
A National Cancer Institute of Canada clinical trials group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Canada | 2001 |
Uracil with ftorafur and low dose oral folinic acid in advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; | 2001 |
[Prophylactic effect of UFT in combination with intravesical chemotherapy on the recurrence of superficial bladder tumor].
Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic C | 1992 |
Adjuvant chemotherapy with vinblastine, adriamycin, and UFT for renal-cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Ad | 1992 |
A prospective randomized study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer--intravesical thio-TEPA versus oral UFT.
Topics: Administration, Intravesical; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Proto | 1992 |
[A comparative clinical trial of UFT treatment and intravesical adriamycin instillation to prevent recurrence of superficial bladder cancer].
Topics: Administration, Intravesical; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; | 1992 |
[Prophylactic effect of UFT on the recurrence of bladder cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 1990 |
[A comparative clinical trial of UFT medication and intravesical BCG in the recurrence of superficial bladder cancer. Study Group of UFT and BCG adjuvant therapy for bladder cancer].
Topics: Administration, Intravesical; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined | 1990 |
[Clinical effect of combined chemotherapy with UFT, MMC and OK-432 in recurring or advanced cancer of the digestive organs].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Digestive System Neo | 1989 |
Other Studies
89 other studies available for uracil and Local Neoplasm Recurrence
Article | Year |
---|---|
Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Colonic Neoplasms; Colorectal Neoplasms; | 2022 |
Impact of thoracic esophageal displacement after lobectomy on the continuity of oral adjuvant chemotherapy.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chem | 2022 |
Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasm | 2022 |
N2 Lymph Node Metastasis Is a Useful Predictor of Recurrence in Patients With Stage III Rectal Cancer Undergoing Adjuvant Chemotherapy Using Tegafur-uracil/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Humans | 2023 |
Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2023 |
Oral uracil-tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early-stage non-small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuva | 2023 |
Metronomic chemotherapy with tegafur-uracil following radical resection in stage II colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2021 |
[Long-Term Survivor with Recurrent Gastric Cancer Using Trifluridine/Tipiracil as a Late-Line Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Neo | 2020 |
[Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations | 2021 |
Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2017 |
Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Creatinine; Drug Combinations; Female; Humans; | 2018 |
Identification of Predictors of Recurrence in Patients with Lower Rectal Cancer Undergoing Neoadjuvant Chemotherapy: A Direct Comparison of Short-Course and Long-Course Chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2019 |
Toxicity and Efficacy of Sequential Chemotherapy in Patients with p-stage I Non-small Cell Lung Cancer that Recurring during Postoperative Tegafur-Uracil Adjuvant Chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2018 |
[A Case of Spontaneous Esophageal Rupture That Required Operation during Adjuvant Chemotherapy for Transverse Colon Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colon, Transverse; Col | 2018 |
Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Co | 2019 |
Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Chemoembol | 2019 |
CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Chemoradiotherapy; | 2014 |
Antitumor activity of 7-aminocarboxycoumarin derivatives, a new class of potent inhibitors of lactate influx but not efflux.
Topics: Animals; Breast Neoplasms; Colorectal Neoplasms; Coumarins; Female; HCT116 Cells; Humans; Lactic Aci | 2014 |
Repeat hepatectomy for intrahepatic recurrence of cholangiolocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2013 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2014 |
Multicenter observational cohort study of post-operative treatment for completely resected non-small-cell lung cancer of pathological Stage I (T1 >2 cm and T2 in TNM classification version 6).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuva | 2015 |
Volume-reserving Surgery after Photodynamic Therapy for Biliary Papillomatosis: A Case Report.
Topics: Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Embolization, Therapeutic; Gam | 2015 |
Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neop | 2016 |
Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Combinations; Female; | 2016 |
[A Case of Primary Acinic Cell Carcinoma(ACC)of the Breast].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Acinar Cell; Chemothera | 2016 |
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbama | 2017 |
Retrospective analysis of surgical resection after induction chemotherapy for patients with T4b squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2008 |
[Two cases of squamous cell carcinoma of upper urinary tract with hypercalcemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2008 |
[Two cases of advanced hepatocellular carcinoma (HCC) effectively treated by oral UFT administration].
Topics: Administration, Oral; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carc | 2008 |
[Three cases of complete response after treatment with UFT and leucovorin for recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Ne | 2008 |
Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap | 2009 |
[Local recurrence after surgical resection of pancreatic cancer effectively treated with combined chemoradiotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bio | 2009 |
Postoperative chemotherapy after neoadjuvant chemoradiation and surgery for rectal cancer: is it essential for patients with ypT0-2N0?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2009 |
Complete remission of multiple recurrent hepatocellular carcinomas by oral administration of enteric-coated tegafur/uracil in a patient with huge hepatocellular carcinoma extending to the inferior vena cava after hepatic resection: analysis of mRNA expres
Topics: Administration, Oral; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality T | 2009 |
Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2009 |
Placement of an expandable metallic stent improves the efficacy of chemoradiotherapy for pancreatic cancer with malignant portal vein stenosis or obstruction.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Con | 2009 |
The necessity of chemotherapy in T3N0M0 colon cancer without risk factors.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col | 2009 |
Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?
Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon H | 2010 |
Uracil misincorporation into DNA and folic acid supplementation.
Topics: Adenoma; Aged; Alcohol Drinking; Aspirin; Colonoscopy; Colorectal Neoplasms; Dietary Supplements; DN | 2010 |
[A case report of combined hepatocellular-cholangiocarcinoma whose lymph node recurrence effectively treated with UFT].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neo | 2009 |
The impact of preoperative chemoradiotherapy on advanced low rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Combined Modal | 2010 |
[A case of recurrent sigmoid colon cancer with adrenal and para-aortic lymph node metastasis successfully treated by operation and chemotherapy].
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, | 2010 |
[An experience of curative resection of local recurrent rectal cancer with high-level sacrectomy after preoperative chemo-radiation therapy].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Com | 2010 |
[A case of local relapsed rectal cancer responding to low-dose S-1].
Topics: Administration, Oral; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2010 |
[A case of salvage treatment for local recurrence of squamous cell anal carcinoma after chemoradiation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Comb | 2010 |
[A long-term survival case of local recurrence of breast cancer treated with combined modality therapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; An | 2010 |
[Simultaneous detection of both non-Hodgkin's lymphoma cells and breast cancer cells in pleural effusion--a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; | 2003 |
[A case of hepatic metastasis and local recurrence from rectal cancer responding to hepatic arterial infusion and systemic chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administrat | 2003 |
Preoperative radio/chemo-radiotherapy in combination with intraoperative radiotherapy for T3-4Nx rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Cohort Studies; Combined Modality Thera | 2004 |
Uracil-tegafur in early-stage lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Humans; Lung | 2004 |
Spontaneous regression of recurrent squamous cell carcinoma of the tongue.
Topics: Aged; Carcinoma, Squamous Cell; Drug Combinations; Humans; Male; Neoplasm Recurrence, Local; Neoplas | 2004 |
[A case of long-term survivor with multiple pulmonary metastases of HCC after hepatic resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Combinati | 2004 |
The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2006 |
[Efficacy of tegafur/uracil plus oral leucovorin therapy for advanced or recurrent colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 2005 |
[Clinical study of ambulatory patient cancer chemotherapy for advanced colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
[A case of recurrent colon cancer responding completely to uracil/tegafur (UFT) plus oral leucovorin (LV) therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colonic Neoplasms; | 2005 |
[A case of recurrent pancreatic cancer responding to TS-1 combined gemcitabine chemotherapy after UFT combined gemcitabine chemotherapy resulting progressive disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Co | 2006 |
[Retrospective analysis of tegafur/uracil (UFT) plus oral leucovorin (LV) regimen in patients with advanced colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2006 |
Accelerated radiotherapy and larynx preservation in favorable-risk patients with T2 or worse hypopharyngeal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Follow-Up Studies; Humans; Hypophar | 2007 |
Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2007 |
Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Combined Modality Therapy; Cys | 2009 |
[Effective cases of advanced endometrial and recurrent ovarian cancers treated with oral administration of UFT].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Tra | 1984 |
[Clinical trial of UFT in recurrent or advanced cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasm | 1982 |
Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Che | 1995 |
[Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer].
Topics: Administration, Intravesical; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; | 1994 |
[Prognostic effect of PyNPase (pyrimidine nucleoside phosphorylase) activity in breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 1998 |
[Combined chemotherapy with low-dose cisplatin, tegafur and uracil in a case with neck recurrence of laryngeal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1998 |
Combination therapy for advanced breast cancer: cyclophosphamide, doxorubicin, UFT, and tamoxifen.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brea | 1999 |
[A case of recurrent ampullary carcinoma of the papilla of Vater, in which a complete response was induced by combination therapy using radiotherapy and oral chemotherapy employing UFT and cyclophosphamide].
Topics: Administration, Oral; Adult; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Combi | 1999 |
[A case of breast cancer with multiple metastases successfully treated by medroxyprogesterone acetate with intermittent intra-arterial infusion low-dose chemotherapy to hepatic metastasis].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bre | 2000 |
[Sharp decline in plasma CEA and reduction of liver metastasis after UFT administration in a patient with recurrent gastric cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembr | 1992 |
Can cytokines prolong survival in ampullary neuroendocrine carcinomas?
Topics: Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Thera | 1992 |
[A case of renal cell carcinoma with lung metastasis and local recurrence effectively treated with nephrectomy and UFT].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; C | 1992 |
[Combination therapy with 5-FU, etoposide and CDDP (FEP regimen) in advanced primary and recurrent gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 1992 |
[A case of local recurrence of rectal cancer successfully treated by UFT combined with two-route CDDP chemotherapy under the AT-II induced hypertension].
Topics: Adenocarcinoma; Administration, Oral; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols | 1991 |
[A case of recurrence of a metastatic brain tumor which disappeared due to chemotherapy only].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Renal Cell; Humans; Kidn | 1990 |
[Responsiveness of gynecological malignancies to oral antitumor agents in subrenal capsule assay and individualization of oral adjuvant chemotherapy].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 1990 |
[Evaluation of subselective intraarterial infusion chemotherapy in advanced gastric cancer and recurrence case-evaluated on factors other than direct effects].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 1990 |
[Results of prophylactic intra-arterial infusion chemotherapy after hepatic resection in colorectal metastases].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 1990 |
[UFT-MT therapy in advanced or recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middl | 1990 |
[A case of local recurrent breast cancer with complete response to combination of systemic chemotherapy and topical use of adriamycin ointment].
Topics: Administration, Topical; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin | 1990 |
[Combined chemotherapy and radiotherapy in recurrent tumors of the head and neck region].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 1987 |
Improved results in the treatment of nasopharyngeal carcinoma using combined radiotherapy and chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, | 1989 |
[Vincristine, adriamycin, mitomycin-C and UFT (VAM-UFT) therapy in progressive or recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Adm | 1989 |
[Combination chemotherapy using low-dose epirubicin and vindesine in patients with metastatic breast cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1988 |
[PMU therapy of recurrent gastric cancer. A case report].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; | 1986 |
[Clinical study of combination chemotherapy using carboquone, cisplatin, UFT and OK-432 in 7 cases of advanced gastric cancers and a relapsed gastric cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carbazilquinone; | 1988 |
[On the experimental prevention of recurrence and metastaais of malignant tumor with methacil and endoxan].
Topics: Animals; Cyclophosphamide; Neoplasm Metastasis; Neoplasm Recurrence, Local; Rats; Sarcoma, Experimen | 1967 |